Vanda Pharmaceuticals (VNDA) — AI Analysis & Mentions
VNDA has been discussed in 1 daily market analyses (first mention Feb 22, 2026, latest Feb 22, 2026).
Current Snapshot
AI Analysis Mentions (1 total)
Vanda Pharmaceuticals soared 38% after FDA approval for Bysanti, a major milestone for the company. Sentiment is 'Bullish' (0.87). While news-driven leaps are tempting, long-term winners in pharmaceuticals must follow through with successful commercialization and pipeline development.